First presentation of Phase II data for the development compound gadoquatrane, Bayer’s investigational MRI contrast agent, at RSNA 2023 / Publication of a novel health economic model, analyzing cost effectiveness and capacity needs of supplemental screening modalities for dense breasts / Comprehensive program focused on innovation in AI – hosted jointly by teams from Calantic™ Digital Solutions and Blackford Analysis / Bayer’s Experience Center offers immersive tour through radiology clinic of the future
Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline of its investigational contrast agent as well as new innovations in the area of Artificial Intelligence (AI). The company announced that new clinical data for gadoquatrane, Bayer’s investigational macrocyclic gadolinium-based compound currently in Phase III development, will be presented at the 2023 Radiological Society of North America (RSNA) Annual Meeting – taking place from November 26 to 30, 2023, in Chicago, USA. Bayer also announced the results of a recently published paper on the cost effectiveness of supplemental screening methods for women with dense breasts in the U.S., to provide greater certainty around the clinical and economic benefits of supplemental screening methods. In addition, Bayer announced four collaboration agreements with the aim to further expand the offering on its medical imaging platform Calantic™ Digital Solutions.
The activities at RSNA reflect Bayer’s commitment as a leading company in key areas of radiology to address today’s industry challenges and accelerate innovation for the benefit of patients and their clinicians, including harnessing the vast potential of artificial intelligence (AI).
New clinical data for investigational contrast agent gadoquatrane being presented at RSNA 2023
International Multicenter Phase 2 Dose Finding Study of Gadoquatrane: A Dose of 0.04 mmol Gd/ kg body weight (bw) of Gadoquatrane Has Similar Efficacy to 0.1 mmol Gd/kg bw of Gadobutrol
Abstract No. 3922, Session No. W7-SSNR13
- Background: Gadoquatrane, Bayer’s investigational macrocyclic gadolinium-based compound currently in Phase III, has the potential to enable a substantially lower gadolinium dose.
- The Purpose of this Phase II study was to establish a dose of gadoquatrane with similar efficacy as gadobutrol for use in CE-MRI, which is the standard of care in diagnostic imaging procedures of the Central Nervous System (CNS), in adult patients with known or highly suspected CNS lesions.
- The Phase II results supported the further development of gadoquatrane with a dose of 0.04 mmol Gd/kg body weight in a broad Phase III program.
New insights into cost effectiveness and capacity needs of supplemental screening modalities for dense breasts
During RSNA 2023 Bayer will announce the publication of a novel health economic model in the Journal of Medical Economics, funded by Bayer, analyzing cost effectiveness and infrastructural capacity of supplemental imaging modalities for women with dense breasts at average and intermediate risk of breast cancer. While ultrasound had the lowest incremental cost-effectiveness ratios, magnetic resonance imaging (MRI) and contrast-enhanced mammography (CEM) demonstrated the best clinical outcomes, compared to x-ray mammography or digital breast tomosynthesis (DBT) alone. Existing MRI scanner capacity has the potential to meet most of the supplemental screening needs of this population.